Pharmacy Practice
Professor
Use of thermosensitive gel-based tenofovir nanoparticles in a humanized BLT mouse model for HIV prevention. Nebraska Center for Virology Award $50,000/year. 2013-2015. Funded.
BIC+TAF nanoformulation for PrEP in humanized mice. Wareham Research Fund.
Creighton University School of Pharmacy. $25,000/year 2018-2020.
R01AI117740-01 (Destache) 02/01/2015 – 01/30/2019 3.0 calendar mon. NIAID $308,705
Long-acting antiretroviral nanoparticles for HIV prophylaxis.
The goal for this project is to evaluate several antiretroviral drugs incorporated into a nanoparticle formulation for HIV prevention in a Hu-BLT mouse model.
No Cost Extension 1/31/2020
Evaluation of nanomedicines in the treatment of HIV. National Institute of Allergy & Infectious Diseases (NIAID) $434,988 2014-2016. Not funded.
Combination antiretroviral nanoparticles for HIV prophylaxis. National Institute of Allergy & Infectious Diseases (NIAID) $2,315,482 2014-2018. Not funded.
Evaluation of ASP and rapid diagnostic test on S. aureus bacteremia outcomes. Merck Inc.
$58,100. 2017 Not Funded.
EPSCoR Major Instrument Grant. Dr. E. Jeffrey North co-principle investigator. National Science Fountation. $472,372 2016-2020. Not Funded.
Design and evaluation of CNS-targeted Antiretroviral Nanoparticles. A. Shibata (PI) Haddix award 1/4/18 $15,000. Funded.
R15 AI118550-01 (Shibata A) 02/01/2015-01/30/2018 0.06 calendar mon NIAID $300,000 Integrase inhibitor combination nanomicrobicide for prevention of HIV infection. The goal of this project is to evaluate dolutegravir+cellulose acetate phalate for HIV prevention as a vaginal gel.
Combination antiretroviral nanoparticles for treatment in a humanized mouse model of HIV. Nebraska Smoking Tax Fund (LB692) sponsored by Creighton University. $74,850 2013-2014 Funded.
Efficacy of combination antiretroviral nanoparticles in a mouse model of HIV-1. Clinical and Translational Research Grant Program, Creighton University $37,500 2011-2012 Funded
Determination of the Efficacy of Nanoparticle driven Antiretroviral Drug Delivery Systems using Cellular Model Systems. Annemarie Shibata, Ph. D., principle investigator. $10,000 CU President’s Faculty Research Fund. 2011-2012. Funded
Warfarin Dosing: Pharmacogenetic Algorithm Compared to Pharmacist Dosing. Angie Goeser, Pharm. D. principle investigator. American College of Clinical Pharmacy Foundation. $20,000 2006-2007. 20% effort. CU Internal Funding $4,000
BIC+TAF NP for HIV-1 Prevention. Wareham Research Award. Creighton University School of Pharmacy & Health Professions. $50,000 2018-2020. Funded
Eradication of HIV-1 brain reservoirs in the BLT-mouse model. Charles Wood, Ph. D. principle investigator. $3,670,661 NAID 2014-2019. Not funded.
R56AI095115-01
09/01/2011-08/30/2013
NIH/NIAID
Title: Once monthly antiretroviral nanoparticles for HIV-1 treatment.
The goal of this project was to evaluate antiretroviral drugs incorporated into a nanoparticle formulation for HIV treatment in a Hu-BLT mouse model
3R15AI076039-01A1S1
01/03/2010-01/02/2011
NIH/NIAID
Title: Pharmacology of Antiretroviral Nanoparticle Micelles
The goal of this project was to investigate the use of a hollow-fiber system to evaluate the pharmacokinetics of antiretroviral nanoparticles.
Combined nanofabrications for antiretroviral prophylaxis. Dr. Annemarie Shibata co-principle investigator. President’s Faculty Research Fund. Creighton University $15,000 2012-2013.
Clinical Assessment Program and Teflaro Utilization Registry (CAPTURE). A multicenter, retrospective cohort study to characterize the use of Teflaro in the treatment of patients with acute bacterial skin and skin structure infection or community-acquired pneumonia. Cerexa, Inc. Funded. 2012-2015.
Clinical and economic impact associated with agents used for treatment of suspected or documented infections due to methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and Pseudomonas aeruginosa. Cubist Pharmaceuticals, Inc. Funded. 2012-2013.
Phase 2, Open-Label, Randomized, Multicenter Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients with Complicated Bacteremia or Documented Infective Endocarditis. Allergan Pharmaceuticals, Inc. 2017-2018.
Combined antiretroviral drug and CCR5 antibody nanoparticle for HIV-1 prevention. Nebraska cigarette tax LB629. 2017-2019. $74,948. Funded.
K-2 research award for NHSN AR and AU monitoring. Nebraska Department of Health. $75,000 2017-2018 Funded.
K-2 renewal award. Nebraska Department of Health. $25,000 2018-2019 Funded.